Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Production is transitioning from Gropello Cairoli, Italy, within the Farmabios business unit.
By: Patrick Lavery
Content Marketing Editor
Editor’s Take: Creating a fully integrated production platform allows a company to align with evolving customer needs.
Axplora is strategically consolidating ursodeoxycholic acid (UDCA) manufacturing at its Vizag, India site, part of the company’s PharmaZell business unit.
Transitioning from the Gropello Cairoli, Italy site in the Farmabios business unit, consolidation should finish by the end of 2026. Axplora previously announced a €6.5 million (US$7.51 million) investment to expand UDCA manufacturing capacity in Vizag in August 2025.
UDCA, an API derived from bile acid, sees wide usage in therapies to treat chronic liver and gallbladder diseases. Axplora says global UDCA demand is growing—mostly driven by increased diagnoses and treatment of chronic liver conditions.
Therefore, one effect of the Vizag investment is creating a fully integrated production platform, from bile sourcing to API manufacturing. At this site, manufacturing takes Axplora’s proprietary, enzymatic green chemistry synthesis route. This reduces process steps and minimizes solvent and reagent use compared with conventional approaches.
In that way, Vizag’s manufacturing standards are identical to Gropello’s; Vizag has already been awarded an EcoVadis Silver sustainability rating.
Axplora CEO Martin Meeson said the consolidation highlights the company’s ability to align investments with changing customer needs.
“This decision reflects the strategic advantage of Axplora’s integrated global network,” Meeson said. “By consolidating UDCA manufacturing at Vizag, we are creating a more streamlined and scalable supply platform that strengthens resilience.”
“Our Vizag site has become an increasingly important strategic hub,” Anant Barbadikar, President of PharmaZell—Operations, said. “This consolidation reflects the technical expertise, operational excellence, and regulatory track record of our Indian teams.”
Overall, Axplora operates nine API manufacturing sites across Europe and India. This provides multi-site capacity to the company’s partners around the globe.
Contract Pharma is the premier media outlet linking contract service providers and their pharma/biopharma sponsors.
Copyright © 2026 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy.
The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.
Enter your account email.
A verification code was sent to your email,
Enter the 6-digit code sent to your mail.
Didn’t get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
Leave a Reply